Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population

Journal of Hepatology

Volumn 66, Issue 1, 2017, Pages 19-27

  Innes, Hamish ^a,b   McDonald, Scott ^a,b   Hayes, Peter ^c   Dillon, John F ^d   Allen, Sam ^e   Goldberg, David ^a,b   Mills, Peter R ^f   Barclay, Stephen T ^g   Wilks, David ^h   Valerio, Heather ^a,b   Fox, Ray ⁱ   Bhattacharyya, Diptendu ^j   Kennedy, Nicholas ^k   Morris, Judith ^l   Fraser, Andrew ^m   Stanley, Adrian ^g   Bramley, Peter ⁿ   Hutchinson, Sharon J ^a,b  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e CROSSHOUSE HOSPITAL   (United Kingdom)

^f GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^g GLASGOW ROYAL INFIRMARY   (United Kingdom)

^h WESTERN GENERAL HOSPITAL   (United Kingdom)

ⁱ Brownlee Centre   (United Kingdom)

^j Kirkcaldy Hospital   (United Kingdom)

^k MONKLANDS HOSPITAL   (United Kingdom)

^l SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^m ABERDEEN ROYAL INFIRMARY   (United Kingdom)

ⁿ Stirling Royal Infirmary   (United Kingdom)

more..

Author keywords

Cure; Epidemiology; Excess mortality; Hepatitis C

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ALL CAUSE MORTALITY; ARTICLE; CAUSE SPECIFIC MORTALITY; DEATH; DRUG USE; FEMALE; HEALTH HAZARD; HEPATITIS C; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; STANDARDIZED MORTALITY RATIO; SURVIVAL; AGED; CAUSE OF DEATH; CHRONIC HEPATITIS C; FACTUAL DATABASE; LIVER TUMOR; MIDDLE AGED; PROGNOSIS; RISK FACTOR; SCOTLAND; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL AGENTS; CAUSE OF DEATH; DATABASES, FACTUAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTORS; SCOTLAND; SUSTAINED VIROLOGIC RESPONSE;

EID: 84995654500     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.08.004     Document Type: Article

References (33)

1. [1] Pawlotsky, J.-M., New hepatitis C therapies: the toolbox, strategies and challenges. Gastroenterology 146 (2014), 1176–1192.
2. [2] Pawlotsky, J.-M., Feld, J.J., Zeuzem, S., Hoofnagle, J.H., From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62 (2015), S87–S99.
3. [3] Pearlman, B.L., Traub, N., Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 52 (2011), 889–900.
4. [4] “Pamela Anderson says: I'm cured of Hep C”. Accessed December 2015. http://www.thesun.co.uk/sol/homepage/showbiz/6732270/Pamela-Anderson-cured-of-Hepatitis-C.html.
5. [5] Your moment to cure. Viekira homepage. Accessed January 2016. https://www.viekira.com/.
6. [6] I am hepatitis C cured. Sovaldi homepage. Accessed January 2016. http://www.sovaldi.com/.
7. [7] Hepatitis C virus can be cured in 12 weeks with drug course: study. Accessed December 2015. http://www.huffingtonpost.ca/2015/11/18/hepatitis-c-cure_n_8592704.html.
8. [8] Maylin, S., Martinot-Peignoux, M., Moucari, R., Boyer, N., Ripault, M.P., Cazals-Hatem, D., et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 135 (2008), 821–829.
9. [9] Thein, H., Yi, Q., Dore, G.J., Krahn, M.D., Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48 (2008), 418–431.
10. [10] El-Serag, H.B., Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36 (2002), S74–S83.
11. [11] Aspinall, E., Hutchinson, S.J., Janjua, N.S., Grebley, J., Yu, A., Alavi, M., et al. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. J Hepatol 62 (2015), 269–277.
12. [12] Negro, F., Forton, D., Craxi, A., Sulkowski, M.S., Feld, J.J., Manns, M.P., Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 (2015), 1345–1360.
13. [13] Simmons, B., Saleem, J., Heath, K., Cooke, G.S., Hill, A., Long term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 61 (2015), 730–740.
14. [14] Lambert, P.C., Thompson, J.R., Weston, C.L., Dickman, P.W., Estimating and modelling the cure fraction in population-based cancer survival analysis. Biostatistics 8 (2007), 576–594.
15. [15] Del Maso, L., Guzzinati, S., Buzzoni, C., Capocaccia, R., Serraino, D., Caldarella, A., et al. Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann Oncol 25 (2014), 2251–2260.
16. [16] Van der Meer, A.J., Wedemeyer, H., Feld, J.J., Dufour, J.F., Zeuzem, S., Hansen, B.E., et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312 (2014), 1927–1928.
17. [17] Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. Survival of patients with HCV cirrhosis and sustaeind virologic response is similar to the general population. J Hepatol 64 (2016), 1217–1223.
18. [18] Razavi, H., Waked, I., Sarrazin, C., Myers, R.P., Idilman, R., Calinas, F., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 21 (2014), 34–59.
19. [19] Innes, H.A., McDonald, S.A., Dillon, J.F., Allen, S., Hayes, P.C., et al. Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 62 (2015), 355–364.
20. [20] Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
21. [21] Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.C., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43 (2005), 1130–1139.
22. [22] Lin, Z.H., Xin, Y.N., Dong, Q.J., Wang, Q., Jiang, X.J., Zhan, S.H., et al. Performance of the aspartate aminotransferase-to-platelet-ratio index for the stage of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 53 (2011), 726–736.
23. [23] Innes, H.A., Hutchinson, S.J., Allen, S., Bhattacharyya, D., Bramley, P., Carman, B., et al. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur J Gastroenterol Hepatol 24 (2012), 646–655.
24. [24] Sewell, J.L., Stick, K.M., Monto, A., Hepatocellularcarcinoma after sustained virologic response in hepatitis C patients with cirrhosis on a pretreatment liver biopsy. Eur J Gastroenterol Hepatol. 21 (2009), 225–229.
25. [25] Hirashima, N., Mizokami, M., Orito, E., Koide, T., Itazu, I., Kamuda, K., et al. Case report: development of hepatocellular carcinoma in a patients with chronic hepatitis C infection after a complete and sustained response to interfetron-alpha. J Gastroenterol Hepatol 11 (1996), 955–958.
26. [26] Scherzer, T.M., Reddy, K.R., Wrba, F., Hofer, H., Staufer, K., Steindl-Munda, P., et al. Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C. J Viral Hepat 15 (2008), 659–665.
27. [27] Tabibian, J.H., Landaverde, C., Winn, J., Geller, S.A., Nissen, N.N., Hepatocellular carcinoma in a hepatitis C patients with sustained viral response and no fibrosis. Ann Hepatol 8 (2009), 64–67.
28. [28] Nagaoki, Y., Aikata, H., Nakano, N., Shinohara, F., Nakamura, Y., Hatooka, M., et al. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study. J Gastroenterol Hepatol, 2015, 10.1111/jgh.13236.
29. [29] Innes, H.A., Hutchinson, S.J., Allen, S., Bhattacharyya, D., Bramley, P., Delahooke, T.E., et al. Excess liver-related morbidity of chronic hepatitis C patients who achieve a sustained viral response and are discharged from care. Hepatology 54 (2011), 1547–1558.
30. [30] Omland, L.H., Christensen, P.B., Krarup, H., Jepson, P., Weis, N., Sorensen, H.T., et al. Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study. PLoS ONE, 6, 2011, e22476.
31. [31] Omland, L.H., Osler, M., Jepsen, P., Krarup, H., Weis, N., Christensen, P.B., et al. Socioeconomic status in HCV infected patients – risk and prognosis. Clin Epidemiol 5 (2013), 163–172.
32. [32] El-Serag, H.B., Kanwal, F., Richardson, P., Kramer, J., Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology 64 (2016), 130–137.
33. [33] Stephan Wiktor. Hepatitis B and C public policy association meeting: EU HCV Brussels, 17th February 2016. http://www.hcvbrusselssummit.eu/material/summit-podcast (accessed April 2016).